This bibliometric analysis has examined the development of macrophage research in liver fibrosis from 2007 to the present. The analysis reveals a growing trend in publications related to liver fibrosis and macrophages. This increase mirrors a similar trend observed in a previous bibliometric study focusing on liver fibrosis treatment (
20), suggesting a shift towards more experimental research rather than review articles in this field.
Apart from Italy and South Korea, all other countries within the top ten in terms of productivity also ranked in the top ten for centrality. Meanwhile, Switzerland and Austria demonstrated high centrality despite not appearing in the list of countries with the highest number of publications. This discrepancy suggests that the publication volume of the top countries may not directly correlate with their global influence. Additionally, China led in the number of publications, with significant contributions from one author, Li Jun, from the Shanghai Institute of Technology. However, China's centrality was only 0.07, and Chinese authors were absent from the list of highly cited articles, suggesting that the research quality from China in this field could be improved. This situation could be attributed to the limited number of scientific research platforms in previous years. Nevertheless, with China's growing national strength and increased investment in scientific research in recent years, its research infrastructure has seen significant improvements, leading to an increase in high-quality publications from China (
21). Regarding collaboration, there was a strong linkage between the two productive countries, the USA and China, highlighting that international inter-agency collaboration and cooperation could be effectively enhanced to further advance development in this field.
The review titled “Liver Macrophages in Tissue Homeostasis and Disease” (
22) by Oliver Krenkel and Frank Tacke, published in Nature Reviews Immunology, received the highest number of citations, totaling 104. Another significant review, “Mechanisms of hepatic stellate cell activation” (
23) by Takuma Tsuchida, was featured in Nature Reviews Gastroenterology and Hepatology. This review focused on the activation of hepatic stellate cells as a pivotal step toward the proliferation of fibrous myofibroblasts. It explored the intricate complexity and adaptability of hepatic stellate cell activation, covering a range of processes, including autophagy, endoplasmic reticulum stress, oxidative stress, retinol and cholesterol metabolism, epigenetics, and receptor-mediated signaling pathways. It also discussed the role of extracellular signals from macrophages, hepatocytes, sinusoidal endothelial cells, natural killer cells, natural killer T cells, platelets, and B cells in the activation process. Frank Tacke authored another influential piece, “Targeting hepatic macrophages to treat liver diseases,” published in the Journal of Hepatology. This review highlighted the diversity of hepatic macrophages in terms of their ontogenesis, differentiation, and function. It emphasized the importance of understanding this heterogeneity and the distinct macrophage subsets for the critical regulation of inflammation, fibrosis, and cancer, suggesting new avenues for liver disease treatment. Additionally, Frank Tacke's publication “Macrophage Heterogeneity in Liver Injury and Fibrosis” (
12) called for a deeper understanding of the mechanisms governing liver macrophage diversity and monocyte subset recruitment. It proposed that promoting restorative macrophage polarization and influencing unique macrophage effector functions could lead to innovative therapies targeting specific macrophage subsets for liver injury and fibrosis.
Inactivating stellate cells or myofibroblasts, which are pivotal in fibrosis activation, could represent a novel approach for fibrosis regression, including the induction of astrocyte apoptosis. Macrophages contribute to fibrogenesis by secreting TGFβ and other agonists. Nonetheless, they also facilitate fibrosis regression by releasing collagenase to dissolve fibrous scarring and by inducing astrocyte apoptosis and inactivating stellate cells or myofibroblasts. This dual role of macrophages, promoting fibrogenesis on the one hand and aiding fibrosis regression on the other by secreting substances like collagenase, underscores their potential as targets for fibrosis treatment (
24). A thorough review of highly cited papers in this field enables a swift and comprehensive understanding of the current status and recent advancements in related research.
Regarding influential authors, Scott L. Friedman has been cited most frequently in this domain, while Frank Tacke is recognized as the most prolific author, highlighting their significant contributions to the study of macrophages and liver fibrosis. Scott L. Friedman has underlined the critical role of hepatic stellate cell activation in identifying targets for antifibrotic therapy. He also noted the importance of improving biomarkers and defining clinical trial endpoints more clearly to expedite drug approval processes (
25). Furthermore, there's a pressing need for progress in validating non-invasive markers for monitoring fibrosis progression and regression, which could supplant biopsies and reduce the duration of clinical trials (
26). Frank Tacke has identified soluble CD163, soluble TREM2, and sialic acid-binding immunoglobulin-like lectin-7 as potential macrophage-mediated biomarkers and has highlighted the role of macrophages in facilitating communication between different organs and compartments (
27).
Keyword analysis may highlight the hotspots in this field. Liver fibrosis, hepatic stellate cells, inflammation, injury, macrophages, and Kupffer cells are all closely associated with liver fibrosis. Burst keywords like macrophage polarization, gut microbiota, tumor-associated macrophages, and immune cells indicate emerging trends in this area. We will explore these keywords further and reveal potential directions for future research as follows.
Fibrosis typically follows inflammation in nearly all cases, with the notable exception of elbow tendinosis, and involves both the innate and adaptive immune systems (
28). Inflammation serves as the initial pathogenesis after liver injury, triggering monocyte/macrophage recruitment, macrophage polarization, hepatic stellate cell activation, and ultimately, liver fibrosis. Immune cells play a crucial role in regulating and balancing the fibrotic process, with T helper 2 cells and IL-4- and IL-13-activated macrophages being vital in type 2 immune responses (
29).
In the experimental model of liver fibrosis, activated hepatic stellate cells and portal fibroblasts account for 90% of collagen-producing cells, highlighting their role as the primary fibroblast sources (
30,
31). Hepatic stellate cells (HSCs) are activated by molecular signals such as TGF-β, Galectin-3, CCL2, and CCL5. Macrophages demonstrate considerable plasticity and can polarize into various phenotypes in response to different microenvironmental stimuli (
32).
Activation of the PI3K/Akt pathway leads to the expression of anti-inflammatory cytokines, thus encouraging the development of the M2-like phenotype, which aids in tissue repair and the resolution of inflammation. On the other hand, blocking the PI3K/Akt pathway can promote the M1-like phenotype, worsening liver damage (
33).
The gut microbiota has recently become a focal point of research. Bile acids play a role in the progression of liver diseases by influencing the function of gut microbiota and immune cells (
34). Yang Ming and their team created a clinically relevant murine model of NASH using a typical Western-type diet, facilitating the investigation of NASH pathogenesis. Additionally, the PR119/TAK1/NF-κB/TGF-β1 signaling pathway mediates the effects of 2-oleoylglycerol on macrophage priming and the subsequent activation of hepatic stellate cells (
35).
Tumor-associated macrophages can either activate or inhibit several signaling pathways in hepatocellular carcinoma (HCC) cells, including NF-κB, IL-6/STAT3, Wnt/β-catenin, TGF-β1/BMP, and ERK1/2. They achieve this by secreting cytokines and exosomes and overexpressing related proteins, thereby influencing the proliferation, invasion, and migration of cancer cells, angiogenesis, and the progression of liver fibrosis (
36). Consequently, these macrophages play a role in various stages of both liver fibrosis and tumor progression (
37).
Macrophages have traditionally been categorized into “pro-inflammatory” M1 and “immunoregulatory” M2 macrophages (
38). Yet, this classification does not fully capture the complex roles of macrophages in both the development and resolution of liver fibrosis. In the last decade, high-resolution techniques such as single-cell RNA sequencing (scRNA-seq) (
39), spatial proteomics, fate mapping experiments (
40), and in vivo microscopy have greatly enhanced our understanding of macrophage origins, activation, functions, and the coexistence of pro-inflammatory and restorative macrophage phenotypes during homeostatic balance (
41).
Current approaches to treating liver fibrosis include macrophage-related molecular therapies and macrophage infusion therapies (
42). Nanoparticles facilitate cell-to-cell communication by carrying bioactive cargoes, such as nucleic acids, proteins, and lipids (
43). Non-invasive tests, like serum-based biomarkers (
44) and precision therapies involving drug and gene delivery (
45), are emerging trends in this area.
5.1. Limitations
Our bibliometric analysis has some limitations. Firstly, we sourced all papers from the WoSCC, yet other databases also hold significant academic value. Secondly, our analysis was limited to documents in English, potentially excluding high-quality research published in other languages. Thirdly, we restricted our literature review to articles and reviews, excluding other document types like reports and comments, which might lead to potential omission bias. Nonetheless, despite these limitations, the integrity and reliability of our analysis remain robust, providing valuable insights for future research in this field. We hope that future studies will encompass a broader range of databases and offer a more comprehensive view of global research efforts on macrophage-mediated liver fibrosis.
5.2. Conclusions
In conclusion, research on macrophages in liver fibrosis is thriving. China is at the forefront in terms of the total number of published articles, while Germany is leading in citation frequency. This study highlighted key researchers and institutions globally involved in studies on macrophage-mediated liver fibrosis. Hepatology emerged as the most prolific journal in this research domain, receiving the highest number of citations. Importantly, studies focusing on cytokines and pathways offer promising avenues for treating liver fibrosis. Understanding how to regulate the diversity of hepatic macrophages, including the recruitment of monocyte subsets, encouraging restorative macrophage polarization, or influencing unique macrophage effector functions, could lead to novel targeted therapies for liver injury and fibrosis. Research on macrophage-based treatments is poised to become a focal point and is expected to gain increasing attention.